5 Osteogenesis Imperfecta Clinical Trials in Fairfax, VA (2026)

Q: How do I join a clinical trial in Fairfax?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Fairfax research site will contact you.

Recruiting Osteogenesis Imperfecta Studies in Fairfax

NCT07227116Recruiting

Evaluating the Status of Complex Aneuploidy to Locate Additional Transferrable Embryos

This study aims to evaluate the reproductive potential of embryos classified as "complex aneuploid" (involving three or more abnormal chromosomes) or "chaotic" (six or more abnormal chromosomes) throu...

Fairfax, VA280 participantsShady Grove Fertility Reproductive Science Center

View Study Details

NCT06419634Recruiting

Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

The purpose of this study is to assess the safety, tolerability, drug levels, drug efficacy and determine the recommended dose of BMS-986497 as a monotherapy, in double combination with Azacitidine an...

Fairfax, VA105 participantsBristol-Myers Squibb

View Study Details

NCT06462183Recruiting

Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)

Phase 1 study to evaluate safety, tolerability and anti-tumor activity of RGT-61159 in patients with ACC or CRC...

Fairfax, VA105 participantsRgenta Therapeutics Inc

View Study Details

NCT05957367Recruiting

A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies

This is a Phase 1/2, multicenter, open-label (unless otherwise specified in a combination-specific module) study of inlexisertib in combination with anticancer therapies. Modules within the master pro...

Fairfax, VA94 participantsDeciphera Pharmaceuticals, LLC

View Study Details

NCT06805825Recruiting

A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

This open-label clinical trial will evaluate the safety and tolerability of NN3201 in subjects with advanced and/or metastatic solid tumors known to express c-Kit....

Fairfax, VA67 participantsNovelty Nobility, Inc.

View Study Details

About Osteogenesis Imperfecta Clinical Trials in Fairfax

Osteogenesis imperfecta is a group of genetic disorders mainly affecting the bones, causing them to break easily, often from little or no apparent cause. It is caused by defects in collagen production. Treatment includes bisphosphonates, physical therapy, and surgical rodding.

There are currently 5 osteogenesis imperfecta clinical trials recruiting participants in Fairfax, VA. These studies are seeking a combined 651 participants. Research is being sponsored by Shady Grove Fertility Reproductive Science Center, Bristol-Myers Squibb, Rgenta Therapeutics Inc and 2 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Osteogenesis Imperfecta Clinical Trials in Fairfax — FAQ

Are there osteogenesis imperfecta clinical trials in Fairfax?

Yes, there are 5 osteogenesis imperfecta clinical trials currently recruiting in Fairfax, VA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Fairfax?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Fairfax research site will contact you about next steps.

Are clinical trials in Fairfax free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Fairfax studies also compensate for your time and travel.

What osteogenesis imperfecta treatments are being tested?

The 5 active trials in Fairfax are testing new therapies including novel drugs, biologics, and treatment approaches for osteogenesis imperfecta.

Data updated July 13, 2026 from ClinicalTrials.gov